Coursera Spring Sale
40% Off Coursera Plus Annual!
Grab it
Explore groundbreaking research on medical cannabis treatment for autism spectrum disorder through this 58-minute keynote webinar presented by Dr. Bonni Goldstein, Medical Director of Canna-Centers Wellness & Education. Discover how pharmacometabolomics and machine learning are revolutionizing the assessment of medical cannabis efficacy in treating autism-related behavioral symptoms. Learn about the innovative use of Cannabis Responsive biomarkers obtained from saliva samples to measure physiologic changes in metabolites before and after medical cannabis treatment. Examine the identification of 23 potential Cannabis Response biomarkers that showed movement toward typical development patterns, reflecting chemical pathways involved in inflammation, neurotransmission, endocannabinoid signaling, and other neurologic processes. Understand how machine learning techniques determine associations between specific phytocannabinoid compounds (THC, CBD, and CBG), non-cannabinoid cannabis plant molecules with synergistic effects, and compounds that distinguish autism from typical development. Gain insights from Dr. Goldstein's 16 years of experience evaluating thousands of patients for medical cannabis use, with particular expertise in treating children with intractable epilepsy, autism, and cancer. Participate in the live Q&A session to deepen understanding of this emerging treatment modality and its potential for improving clinical decision-making and patient outcomes in autism spectrum disorder management. Earn PACE credits by completing the webinar and following the provided certification process.
